The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated significant effects on low-density lipoprotein (LDL) cholesterol and nonhigh density lipoprotein (HDL) cholesterol. To date, there have been limited reports on the effect of PCSK9 inhibitors on remnant cho...

Descripción completa

Detalles Bibliográficos
Autores principales: Morise, Anthony P., Tennant, Jennifer, Holmes, Sari D., Tacker, Danyel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076932/
https://www.ncbi.nlm.nih.gov/pubmed/30105099
http://dx.doi.org/10.1155/2018/9194736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076932/
https://www.ncbi.nlm.nih.gov/pubmed/30105099
http://dx.doi.org/10.1155/2018/9194736

Ejemplares similares